A compound having FAK inhibitory activity, preparation method and application thereof

By developing pyrrolopyrimidine compounds, the kinase activity of FAK was inhibited, and the problem of inhibiting FAK activity in the prior art was solved, and effective regulation of cell adhesion, migration, invasion and other processes was achieved, which had significant clinical application value.

CN116478168BActive Publication Date: 2024-11-29ZHEJIANG MEDICAL COLLEGE
View PDF 19 Cites 0 Cited by

Patent Information

Application Number
CN202310334894.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-03-31
Publication Date
2024-11-29
Estimated Expiration
2043-03-31

AI Technical Summary

Technical Problem

The prior art is difficult to effectively inhibit the activity of focal adhesion kinase (FAK), which makes it difficult to solve problems such as cell adhesion, migration, invasion, proliferation and chemotherapy tolerance.

Method used

A class of pyrrolopyrimidine compounds was developed to bind to FAK through specific chemical structures, thereby inhibiting their kinase activity. These compounds may be used alone or in combination with other drugs to enhance therapeutic effects.

Benefits of technology

These compounds significantly inhibit the kinase activity of FAK, thereby slowing down the adhesion, migration, invasion and other processes of cell adhesion, reducing chemotherapy tolerance, and have high clinical application value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116478168B_ABST
    Figure CN116478168B_ABST
Patent Text Reader

Abstract

The present invention discloses a compound having FAK inhibitory activity, a preparation method thereof, and an application thereof in preparing a pharmaceutical preparation for preventing or treating a disease caused by abnormal FAK protein. Specifically, the present invention describes a compound of formula I. The compound having FAK inhibitory activity provided by the present invention can be widely used in preparing a pharmaceutical preparation for preventing or treating a disease caused by abnormal FAK receptor.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of small molecule drugs, and in particular, to pyrrolopyrimidine compounds that inhibit focal adhesion kinase (FAK) (also known as protein tyrosine kinase 2 (PTK2) and VEGFR3), and to pharmaceutical compositions containing such compounds, as well as methods for synthesizing and using such compounds. Background Art

[0002] Directed cell migration is important in many physiological and pathological processes, including embryonic development, wound healing, angiogenesis, tumor invasion and metastasis. Extracellular signal transduction that stimulates directed cell movement can be induced by many methods, including transmembrane integrins bound to extracellular matrix proteins and the action of growth factors (e.g., EGF, IGF, and VEGF) on the extracellular domains of their cognate receptors.

[0003] FAK is a non-receptor tyrosine kinase that mediates signals from both transmembrane integrins and growth factor receptors. It has been reported that FAK plays a central role in coordinating these different extracellular signals, integrating them in a way that directionally moves cells through their external environment (Tomar and Schlaepfer. Current Opinion in Cell Biology: 2009, 21, 676-683).

[0004] Integrin aggregation or activation of growth factor receptors (e.g., EGFR, IGF-1R, Her2, and VEGFR) promotes FAK autophosphorylation at Y397. Phosphorylated Y397 FAK then binds to c-Src (referred to herein as Src) and Src-mediated FAK phosphorylation occurs at Y576 and Y577 to produce an active FAK-Src complex. Active FAK-Src then promotes signaling through many biochemical pathways, which has an impact on processes such as cell adhesion, migration, invasion, cell survival, proliferation, acquisition of chemotherapy resistance, and metastasis (Brunton and Frame. Current Opinion in Pharmacology: 2008, 8, 437-432 and Chatziz-acharias et al. Expert Opinion in Therapeutic Targets: 2007, 11 (10), 1315-1328).

[0005] Cell adhesion

[0006] Functional studies addressing the role of FAK in cell adhesion have shown that it contributes to focal adhesion assembly (Richardson and Parsons. Nature: 1996, 380, 538-540) and focal adhesion turnover (Fincham et al. Oncogene: 1995, 10 (11), 2247-2252). Inhibition of FAK by RNAi in human and mouse cell lines (resulting in reduced FAK protein levels) has been shown in vitro to reduce cell adhesion to fibronectin / laminin coated well plates (Tsutomu et al. International Journal of Oncology: 2008, 33 (1), 215-224).

[0007] Cell migration

[0008] There is strong evidence that FAK is a key regulator of cell migration (Angelucci and Bologna. Current Pharmaceutical Design: 2007, 13, 2129-2145 and Mitra et al. Nature Reviews Molecular Cell Biology: 2005, 6, 56-68). Cells derived from FAK- / - mouse embryos show reduced migration due to impaired adhesion turnover (et al. Nature: 1995, 377, 539-544). In addition, translocation of FAK from focal adhesions reduces cell migration (Gilmore and Romer. Molecular Biology of the Cell: 1996, 7 (8), 1209-1224), while overexpression in CHO cells stimulates migration (Cary et al. Journal of Cell Science: 1996, 7, 1787-1794). Additionally, inhibition of FAK by RNAi in human and mouse cell lines (resulting in reduced FAK protein levels) has been shown to reduce cell migration in an in vitro haptotactic migration assay (Tsutsumi et al. International Journal of Oncology: 2008, 33(1), 215-224).

[0009] Cell invasion

[0010] It has been demonstrated that FAK activation enhances matrix degradation invasive behavior. FAK-Src signals through apoptosis susceptibility protein (CAS) (Liao et al. Journal of Experimental and Clinical Cancer Research: 2008, 27: 15) to cause the expression of matrix metalloproteinases (MMPs), including MMP2 and MMP9. FAK-Src activation also promotes cell surface expression of MMP-14 by phosphorylating endophilin A2. MMP14 then activates MMP2 to its active form by cleaving pro-MMP2 (Siesser and Hanks. Clinical Cancer Research: 2006, 12 (11), 3233-3237). Highly invasive cancer cells form specialized actin-rich extracellular matrix degradation membrane protrusions called invadopodia, which are rich in matrix degradation proteases such as MMPs. It has been demonstrated that both FAK and Src contribute to the formation of invadopodia (Chan et al. Journal of Chemical Biology: 2009, 185(2), 357-370).

[0011] Cell survival

[0012] It has been shown that FAK plays an important role in cell survival. It has been shown that the activation of FAK inhibits anoikis (apoptosis in response to an inappropriate extracellular matrix environment) (Frisch et al Journal of Cell Biology. 1996, 134 (3), 793-799 and Xu et al Cell Growth and DifFerentiation. 1996, 7 (4), 413-418). Studies have shown that FAK activates multiple downstream pathways in fibroblasts and epithelial cells to inhibit anoikis (Zouq et al. Journal of Cell Science: 2008, 122, 357-367). In human intestinal crypt cells, FAK signals through the binding of β1 integrin, and then binds Src to upregulate the expression of anti-apoptotic proteins Bcl-XL and Mcl-1 through PI3-K / Akt-1 signaling. PI3-K / Akt-1 signaling also downregulates the expression of pro-apoptotic activators Bax and Bak, causes phosphorylation of pro-apoptotic sensitizer Bad and antagonizes the activation of p38β. Dissociation of FAK / Src leads to sustained / enhanced activation of p38β, which is an apoptosis / anoikis driver (Bouchard et al. Apoptosis: 2008, 13, 531-542).

[0013] Cell proliferation

[0014] Reducing the expression of FAK or β1 integrin and thus disrupting the β1-FAK signaling axis leads to a reduction in the initial proliferation of micrometastatic cells distributed in the lung. Using 3D cultured D2 cells, a strong correlation was observed between the phosphorylation of FAK Y397 and Y861 and the proliferation capacity (Shibue and Weinberg. PNAS 2009, 106 (25), 10290-10295). It has been shown that the rate of doubling of HL-60 cells transfected to overexpress FAK is 1.5 times faster than that of control HL-60 cells. Studies have found significant induction of cyclin D3 expression and CDK activity in cells overexpressing FAK. Activated PI3-K / Akt-1 signaling (a process associated with FAK activation in many studies) has been identified as a possible cause of cyclin expression / activation (Yamamoto et al. Cellular Signaling: 2003, 15. 575-583).

[0015] Acquiring chemotherapy resistance

[0016] Exposure of the cisplatin-sensitive ovarian cancer cell line OAW42 to repeated cycles of cisplatin treatment and subsequent recovery resulted in the formation of chemoresistant OAW42-R cells. Studies aimed at determining the cause of this chemo-resistance found that FAK is constitutively active in both sensitive and chemo-resistant cells. However, inhibition of Y397 FAK phosphorylation was induced in OAW42 cells by treatment with cisplatin, but not in OAW42-R cells (Poulain et al. Gynaecologiconcology: 2006, 101, 507-519). The effect of FAK inhibition on chemo-resistance was also studied in vitro and in vivo in taxane-sensitive (SKOV3ip1 and HeyA8) and taxane-resistant (HeyA8-MDR) ovarian cancer cell lines using the FAK inhibitor TAE226, alone and in combination with docetaxel. TAE226 has the following structure:

[0017]

[0018] and described in WO2004 / 080980 and WO2005 / 016894. In vitro, TAE226 inhibits phosphorylation of FAK at Y397 and Y861, inhibits cell growth in a time- and dose-dependent manner, and enhances docetaxel-mediated growth inhibition by 10-fold and 20-fold in taxane-sensitive and taxane-resistant cell lines, respectively. In vivo, FAK inhibition by TAE226 significantly reduced tumor burden in HeyA8, SKOV3ip1, and HeyA8-MDR models (46-64%) compared to vehicle-treated controls. However, the greatest therapeutic effect (85-97% reduction) was observed in all three models by concomitant administration of TAE226 and docetaxel. In addition, the combination of TAE226 and docetaxel significantly prolonged the survival of tumor-bearing mice (Halder et al. Cancer Res: 2007, 67(22), 10976-10983).

[0019] Transfer Potential

[0020] Several studies have investigated the role of FAK protein levels in animal models and their relationship to tumor progression. In a mouse skin carcinogenesis model, the use of FAK+ / - mice reduced FAK protein expression (46%) associated with reduced papilloma formation compared to FAK+ / + wild-type control mice (McLean et al. Cancer Research: 2001, 61, 8385-8389). Using human breast cancer cells, researchers found that FAK siRNA-treated cells were inhibited from metastasizing to the lungs after being implanted in nude mice in an orthotopic manner (Benlimame et al. Journal of Cell Biology: 2005, 171, 505-516). Similar experiments using short hairpin RNA (shRNA) against FAK in 4T1 mouse breast cancer cells inhibited metastasis to the lungs after being implanted in the mammary pad in an orthotopic manner (Mitra et al. Oncogene: 2006, 25, 4429-4440). Inhibition of FAK by dominant negative expression in 4T1 mouse breast cancer cells reduced tumor growth and angiogenesis in mice (Mitra et al. Oncogene: 2006, 25, 5969-5984). The Cre / loxP recombination system was used to destroy FAK function in mammary epithelial cells of a transgenic model of breast cancer, demonstrating that FAK expression is required for the transformation of premalignant hyperplasia into cancer and their subsequent metastasis. The observed reduction in tumor development is further associated with impaired mammary epithelial cell proliferation, indicating that FAK plays a key role in the development of breast tumors (Lahlou et al. PNAS USA: 2007, 104 (51), 20302-20307).

[0021] Based on the above observations, overexpression of FAK mRNA and / or protein has been reported in many human cancers, including colorectal cancer (de Heer. European Journal of Surgical Oncology: 2008, 34 (11), 1253-1261), prostate cancer (Tremblay, L., W. Hauck, et al. International Journal of Cancer: 1996, 68 (2), 164-171), breast cancer (Watermann et al. British Journal of Cancer 2005, 93 (6), 694-698) and melanoma (Hess et al. Cancer Research: 2005, 65 (21), 9851-60). In addition, FAK overexpression is often associated with a more invasive phenotype of these cancers.

[0022] Therefore, there is strong evidence that FAK inhibitors can be used to reduce cell adhesion, cell migration, cell invasion, cell proliferation and chemoresistance. In addition, FAK inhibitors may be useful for inducing apoptosis in cells in an inappropriate extracellular matrix environment and reducing angiogenesis.

[0023] It will be appreciated that the activity of other tyrosine kinases and serine / threonine kinases in combination with FAK activity may be beneficial in treating proliferative diseases, such as cancer.

[0024] For example, the vascular endothelial growth factor receptor VEGFR3 (Flt4) is overexpressed in melanoma patients (with metastatic enzymes in local lymph nodes) (Mouawad et al. European Journal of Cancer: 2009, 45, 1407-1414). Abnormal expression levels of endogenous receptor tyrosine kinase ligands have also been observed in many human cancers. For example, in early invasive cervical cancer, the expression levels of vascular endothelial growth factors C and D (VEGF-C and VEGF-D), VEGFR3 ligands, are significantly associated with lymphatic metastasis and lymphatic invasion (Journal of Experimental & Clinical Cancer Research 2009, 28).

[0025] Therefore, compounds that selectively inhibit FAK and VEGFR3 may be used to treat proliferative diseases, such as cancer.

[0026] Two compounds reported to inhibit FAK are PF-562,271 and PF-573,228.

[0027]

[0028] PF-562,271 is described in WO 2004 / 056786, WO 2004 / 056807, WO 2005 / 023780, WO 2007 / 063384 and Roberts et al. Cancer Res 2008, 68(6), 1935-1944.

[0029] PF-573,228 is described in Slack-Davis et al. J. Biol. Chem. 2007, 282(20), 14845-14852.

[0030] Besides these specifically described compounds, further classes of FAK inhibitors are disclosed in WO2008 / 129380, WO2008 / 115369, WO2009 / 105498, US2010 / 113475, WO2009 / 143389, WO2009 / 071535, WO2010 / 055117, WO2010 / 058030, WO2010 / 058032, WO2007 / 140222 and WO2009 / 024332. Summary of the invention

[0031] The present invention aims to address the deficiencies of the prior art and the inventors have discovered a specific class of compounds that are effective as FAK inhibitors.

[0032] In a first aspect, the present invention provides a compound of the following formula (I):

[0033] A compound of formula (I):

[0034]

[0035] in:

[0036] R1 is selected from:

[0037]

[0038] in:

[0039] R 1-1 Selected from H and OCH3;

[0040] R 1-2 Selected from: OCH3 and

[0041]

[0042] in:

[0043] R N1 is selected from H, C1-3 alkyl and C(═O)Me;

[0044] R N2 is selected from H, C1-3 alkyl and C(═O)Me;

[0045] R N3 is selected from H, C1-3 alkyl and C(═O)Me;

[0046] R 1-3 is selected from H, OCH3 and F;

[0047] And when R1-2 is OCH 3 , R 1-1 and R 1-3Can be OCH3; R 1-4 Selected from H and OCH3;

[0048] R 1-5 , R 1-6 and R 1-7 are independently selected from C and N;

[0049] R 1-8 Selected from H, C1-3 alkyl;

[0050] R 1-9 Selected from C1-3 alkyl;

[0051] R 2 , R 3 are independently selected from C and N;

[0052] R 4 Selected from the group consisting of:

[0053]

[0054] in:

[0055] R 4-1 Selected from H, OCnH2n-1, halogen, SO2CH3, NH2, CONHCH3, CHO, COOCnH2n-1 and C1-3 alkyl;

[0056] R 4-2 Selected from H, OCnH2n-1, halogen, SO2CH3, NH2, CONHCH3, CHO, COOCnH2n-1 and C1-3 alkyl;

[0057] R 4-3 Selected from H, OCnH2n-1, halogen, SO2CH3, NH2, CONHCH3, CHO, COOCnH2n-1 and C1-3 alkyl;

[0058] R 4-4 Selected from H, OCnH2n-1, halogen, SO2CH3, NH2, CONHCH3, CHO, COOCnH2n-1 and C1-3 alkyl;

[0059] Where n=1, 2, 3.

[0060] Further, it is one of the following compounds:

[0061]

[0062]

[0063]

[0064] The term "pharmaceutically acceptable salt" used in the present invention refers to a salt formed by the reaction of the compound shown in the general formula I with an inorganic acid or an organic acid, or a mixed salt thereof. For example, the salt can be prepared by the reaction of the compound shown in the general formula I with an inorganic acid or an organic acid. Among them, the inorganic acid can be hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, aminosulfonic acid and phosphoric acid, etc., and the organic acid can be citric acid, tartaric acid, lactic acid, pyruvic acid, acetic acid, benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, naphthalenesulfonic acid, ethanesulfonic acid, naphthalene disulfonic acid, maleic acid, malic acid, malonic acid, fumaric acid, succinic acid, propionic acid, oxalic acid, trifluoroacetic acid, stearic acid, pamoic acid, hydroxymaleic acid, phenylacetic acid, benzoic acid, salicylic acid, glutamic acid, ascorbic acid, p-aminobenzenesulfonic acid, 2-acetoxybenzoic acid and isethionic acid, etc.

[0065] It should also be understood that hydrates, solvates (e.g., methanolates, ethanolates, ethyl acetates) or stereoisomers thereof, or optical isomers thereof, or isotopic compounds thereof, or prodrugs thereof, or PROTAC conjugates thereof of the compound represented by Formula I of the present invention are also within the scope of the present invention. Related methods are well known in the art.

[0066] The second aspect of the present invention provides a pharmaceutical composition comprising the compound described in the first aspect of the present invention or a pharmaceutically acceptable salt or solvate thereof.

[0067] The third aspect of the present invention provides the use of the above-mentioned compound or its pharmaceutically acceptable salt or solvate and pharmaceutical composition in the preparation of a drug for regulating the catalytic activity of protein kinase, wherein the protein kinase is selected from local adhesion kinase.

[0068] The fourth aspect of the present invention provides use of the above-mentioned compound or its pharmaceutically acceptable salt or solvate and pharmaceutical composition in the preparation of a drug for treating or preventing cancer.

[0069] In a preferred embodiment of the fourth aspect of the present invention, the cancer is preferably lung cancer, colon cancer, breast cancer, prostate cancer or brain glioma.

[0070] The fifth aspect of the present invention provides a method for preparing the compound of the first aspect of the present invention, the method comprising the following steps:

[0071] Synthetic route 1:

[0072]

[0073] Synthetic route 2:

[0074]

[0075] Reaction conditions: (a) benzyl bromide, HCl, t-BuOH, 90°C, 3-5h; (b) aniline analog, Pd(dppf)Cl2, K2CO3, 1,4-dioxane / water (5:1, v / v), 70°C, 8h.

[0076] The structural definition of the substituent groups is the same as above.

[0077] Compared with the prior art, the present invention has the following advantages:

[0078] Compared with the prior art, the invention has novel chemical structure, convenient, economical and fast preparation, high FAK inhibitory activity and extremely high clinical application value. DETAILED DESCRIPTION

[0079] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.

[0080] Example 1 Step 1: Synthesis of Intermediate A:

[0081]

[0082] 2-Chloro-7H-pyrrolo[2,3-d]pyrimidine (9.4 g, 50 mmol) was dissolved in anhydrous t-BuOH (50 mL) and 3-chlorobenzyl bromide (10.6 mL, 60 mmol). After the addition was complete, the reaction was continued for 5 h. After TLC monitoring, the reaction solution was poured into ice water (500 mL) and extracted with EA (500 mL). The organic phase was washed with water twice, dried over anhydrous sodium sulfate, filtered and concentrated. Column chromatography (EA 15%, PE 85%, volume ratio) gave a white solid (14.3 g, yield 90%).

[0083] Step 2: Synthesis of compound B1

[0084]

[0085] 2-Methoxy-4-morpholinylaniline (86 mg, 0.45 mmol), Pd(dppf)Cl2 (34 mg, 10% mmol) and K 2 CO 3(103mg, 0.75mmol) was added to dry 1,4-dioxane (15mL). The temperature was raised to 95℃ under nitrogen protection for 24h. After the reaction was completed, the reaction solution was concentrated by TLC. The residue was dissolved in DCM and filtered through diatomaceous earth. The filtrate was concentrated and purified by preparative TLC (DCM / methanol=20:1, v / v) to obtain a yellow solid (170mg, yield was 82%). 1HNMR(400MHz,DMSO-d6)δ8.64(s,1H),8.08(d,J=8.7Hz,1H),7.63(s,1H),7.40–7.28(m,4H),7.20(dt,J=7.0,1.8Hz, 1H),6.66(d,J=2.5Hz,1H),6.55–6.43(m,2H),5.32(s,2H),3.83(s,3H),3.74(t,J=4.7Hz,2H),3.07(t,J=4.8Hz,4H).

[0086] Compounds B2-B24 were prepared by a similar method to B1.

[0087] Example 2 Preparation of Compound B2.

[0088]

[0089] Preparation analogy B1. 1H NMR (400 MHz, DMSO) δ 8.64 (s, 1H), 8.06 (d, J = 8.8 Hz, 1H), 7.62 (s, 1H), 7.35 (td, J = 9.3, 3.9 Hz, 4H), 7.21 (d, J = 6.8 Hz, 1H), 6.65 (d, J = 2.1 Hz, 1H), 6.56–6.40 (m, 2H), 5.33 (s, 2H), 3.84 (s, 3H), 3.17–3.06 (m, 4H), 2.51–2.45 (m, 4H), 2.25 (s, 3H).

[0090] Example 3 Preparation of Compound B3

[0091]

[0092] Preparation analogy B1. 1 H NMR (400 MHz, DMSO-d 6)δ9.72(s,1H),8.75(s,1H),7.90–7.83(m,2H),7.44(d,J=3.6Hz,1H),7.43–7.29(m,5H),7.23(dt, J=7.2,1.7Hz,1H),6.52(d,J=3.6Hz,1H),5.40(s,2H),3.60(t,J=4.6Hz,4H),3.51(d,J=5.6Hz,4H).

[0093] Example 4 Preparation of Compound B4

[0094]

[0095] Preparation analogy B1. 1H NMR (400 MHz, DMSO) δ 9.15 (s, 1H), 8.65 (s, 1H), 7.63 (d, J = 8.8 Hz, 2H), 7.44-7.31 (m, 4H), 7.22 (d, J = 7.0 Hz, 1H), 6.88 (d, J = 8.9 Hz, 2H), 6.46 (d, J = 3.4 Hz, 1H), 5.34 (s, 2H), 3.42-3.35 (m, 4H), 3.07 (m, 4H), 2.26 (s, 3H).

[0096] Example 5 Preparation of Compound B5

[0097]

[0098] Preparation analogy B1. 1H NMR (400 MHz, DMSO) δ 9.23 (s, 1H), 8.73 (s, 1H), 8.16 (d, J = 9.1 Hz, 1H), 7.98 (d, J = 2.9 Hz, 1H), 7.38 (ddd, J = 19.0, 11.1, 5.7 Hz, 5H), 7.24 (d, J = 7.1 Hz, 1H), 6.50 (d, J = 3.5 Hz, 1H), 5.38 (s, 2H), 3.34–3.29 (m, 4H), 3.11 (d, J = 4.4 Hz, 4H), 2.27 (s, 3H).

[0099] Example 6 Preparation of Compound B6

[0100]

[0101] Preparation analogy B1. 1 H NMR (400 MHz, DMSO-d 6)δ8.63(s,1H),8.03(d,J=8.8Hz,1H),7.60(s,1H),7.35(d,J=13.6Hz,4H),7. 20(d,J=7.0Hz,1H),6.63(s,1H),6.47(dd,J=19.1,6.2Hz,2H),5.32(s,2H),3 .82(s,3H),3.65(d,J=11.8Hz,2H),2.61(t,J=12.4Hz,3H),2.36(s,5H),2.17 (s,3H),1.84(d,J=12.2Hz,2H),1.52(q,J=12.4,12.0Hz,2H),1.22(s,2H).1H NMR (400MHz, DMSO) δ8.63(s,1H),8.04(d,J=8.3Hz,1H),7.60(s,1H),7.36(d,J=13.4Hz,4H),7.21(d,J=5.6Hz,1H),6.63(s,1H),6.56– 6.36(m,2H),5.33(s,2H),3.83(s,3H),3.73–3.47(m,5H),2.74–2.56(m,4H),2.36(m,4H),2.18(s,3H),1.91–1.76(m,2H),1.52(m,2H).

[0102] Example 7 Preparation of Compound B7

[0103]

[0104] Preparation analogy B1. 1 H NMR (400MHz, DMSO) δ9.75(s,1H),8.77(s,1H),8.22(d,J=4.5Hz,1H),7.89(d,J=8.8Hz,2H),7.78(d,J=8.8Hz,2H),7.4 4(d,J=3.6Hz,1H),7.42–7.31(m,3H),7.26(d,J=7.3Hz,1H),6.53(d,J=3.5Hz,1H),5.41(s,2H),2.78(d,J=4.4Hz,3H).

[0105] Example 8 Preparation of Compound B8

[0106]

[0107] Preparation analogy B1. 1H NMR (400 MHz, DMSO) δ 9.39 (s, 1H), 8.76 (s, 1H), 8.20 (d, J = 9.1 Hz, 1H), 8.03 (d, J = 2.9 Hz, 1H), 7.49–7.31 (m, 6H), 7.25 (d, J = 7.1 Hz, 1H), 6.51 (d, J = 3.5 Hz, 1H), 5.39 (s, 2H), 3.85–3.70 (m, 4H), 3.14–3.03 (m, 4H).

[0108] Example 9 Preparation of Compound B9

[0109]

[0110] Preparation analogy B1. 1H NMR (400 MHz, DMSO) δ 8.98 (s, 1H), 8.66 (s, 1H), 7.43–7.23 (m, 4H), 7.16 (t, J = 8.7 Hz, 1H), 6.47 (d, J = 3.4 Hz, 1H), 5.97 (s, 1H), 5.29 (s, 2H), 2.14 (s, 3H), 1.29 (d, J = 6.5 Hz, 9H).

[0111] Example 10 Preparation of Compound B10

[0112]

[0113] Preparation analogy B1. 1H NMR (400 MHz, DMSO) δ 8.97 (s, 1H), 8.66 (s, 1H), 7.43–7.23 (m, 4H), 7.16 (t, J = 8.7 Hz, 1H), 6.47 (d, J = 3.4 Hz, 1H), 5.97 (s, 1H), 5.29 (s, 2H), 4.49 (dt, J = 13.1, 6.5 Hz, 1H), 2.14 (s, 3H), 1.28 (d, J = 6.5 Hz, 6H).

[0114] Example 11 Preparation of Compound B11

[0115]

[0116] Preparation analogy B1. 1H NMR (400 MHz, DMSO) δ 9.39 (s, 1H), 8.76 (s, 1H), 8.20 (d, J = 9.1 Hz, 1H), 8.03 (d, J = 2.9 Hz, 1H), 7.49–7.31 (m, 5H), 7.25 (d, J = 7.1 Hz, 1H), 6.51 (d, J = 3.5 Hz, 1H), 5.39 (s, 2H), 3.85–3.70 (m, 4H), 3.14–3.03 (m, 4H).

[0117] Example 12 Preparation of Compound B12

[0118]

[0119] Preparation analogy B1. 1H NMR (400 MHz, DMSO) δ 9.46 (s, 1H), 8.71 (s, 1H), 7.75 (dd, J = 15.7, 2.3 Hz, 1H), 7.47 (dd, J = 8.7, 2.0 Hz, 1H), 7.36 (dt, J = 9.7, 5.9 Hz, 4H), 7.22 (d, J = 6.7 Hz, 1H), 6.96 (t, J = 9.5 Hz, 1H), 6.49 (d, J = 3.6 Hz, 1H), 5.37 (s, 2H), 2.95 (m, 4H), 2.48 (m, 4H), 2.23 (s, 3H).

[0120] Example 13 Preparation of Compound B13

[0121]

[0122] Preparation analogy B1. 1H NMR (400 MHz, DMSO) δ 9.21 (s, 1H), 8.67 (s, 1H), 8.54 (d, J = 2.6 Hz, 1H), 8.00 (dd, J = 9.1, 2.7 Hz, 1H), 7.69–7.50 (m, 3H), 7.35 (td, J = 10.3, 5.7 Hz, 4H), 7.20 (d, J = 6.9 Hz, 1H), 6.81 (d, J = 9.1 Hz, 1H), 6.47 (d, J = 3.6 Hz, 1H), 5.34 (s, 2H), 3.77–3.66 (m, 4H), 3.35 (m, 4H).

[0123] Example 14 Preparation of Compound B14

[0124]

[0125] Preparation analogy B1. 1H NMR (400 MHz, DMSO) δ 10.20 (s, 1H), 9.25 (s, 1H), 8.67 (s, 1H), 7.70 (s, 1H), 7.57 (d, J = 10.1 Hz, 1H), 7.43–7.31 (m, 4H), 7.22 (d, J = 7.2 Hz, 1H), 6.73 (d, J = 8.4 Hz, 1H), 6.56–6.36 (m, 2H), 5.76 (s, 1H), 5.35 (s, 2H), 3.46 (s, 2H)

[0126] Example 15 Preparation of Compound B15

[0127]

[0128] Preparation analogy B1. 1H NMR (400 MHz, DMSO) δ 9.17 (s, 1H), 8.66 (s, 1H), 8.51 (d, J = 2.4 Hz, 1H), 7.96 (dd, J = 9.0, 2.6 Hz, 1H), 7.46–7.27 (m, 4H), 7.19 (d, J = 6.9 Hz, 1H), 6.80 (d, J = 9.1 Hz, 1H), 6.46 (d, J = 3.5 Hz, 1H), 5.33 (s, 2H), 3.32 (d, J = 27.4 Hz, 4H), 2.47–2.36 (m, 4H), 2.22 (s, 3H).

[0129] Example 16 Preparation of Compound B16

[0130]

[0131] Preparation analogy B1. 1H NMR (400 MHz, DMSO) δ 9.17 (s, 1H), 8.66 (s, 1H), 8.51 (d, J = 2.4 Hz, 1H), 7.96 (dd, J = 9.0, 2.6 Hz, 1H), 7.46–7.27 (m, 3H), 7.19 (d, J = 6.9 Hz, 1H), 6.80 (d, J = 9.1 Hz, 1H), 6.46 (d, J = 3.5 Hz, 1H), 5.33 (s, 2H), 3.32 (d, J = 27.4 Hz, 4H), 2.47–2.36 (m, 4H), 2.22 (s, 3H).

[0132] Example 17 Preparation of Compound B17

[0133]

[0134] Preparation analogy B1. 1H NMR (400 MHz, DMSO) δ 9.74 (s, 1H), 8.74 (s, 1H), 8.23 ​​(d, J = 9.8 Hz, 1H), 7.50–7.19 (m, 6H), 6.52 (d, J = 3.6 Hz, 1H), 5.36 (s, 2H), 3.55–3.44 (m, 4H), 2.48–2.40 (m, 4H), 2.24 (s, 3H).

[0135] Example 18 Preparation of Compound B18

[0136]

[0137] Preparation analogy B1. 1H NMR (400MHz, DMSO) δ9.75 (s, 1H), 8.74 (s, 1H), 8.23 ​​(d, J = 9.8 Hz, 1H), 7.50–7.19 (m, 8H), 6.52 (d, J = 3.6 Hz, 1H), 5.36 (s, 2H), 3.55–3.44 (m, 4H), 2.48–2.40 (m, 4H), 2.24 (s, 3H), 1.38 (s, 1H)

[0138] Example 19 Step 1: Synthesis of Intermediate C

[0139]

[0140] 2-Chloro-7H-pyrrolo[2,3-d]pyrimidine (9.4 g, 50 mmol) was dissolved in anhydrous t-BuOH (50 mL), 3,4,5-trimethoxyaniline (10.6 mL, 60 mmol), Pd(dppf)Cl2 (34 mg, 10% mmol) and K2CO3 (103 mg, 0.75 mmol) were added to dry 1,4-dioxane (15 mL). The temperature was raised to 95 °C under nitrogen protection and reacted for 24 h. After the reaction was completed, the reaction solution was concentrated by TLC. The residue was dissolved in DCM and filtered through diatomaceous earth. After the filtrate was concentrated, it was purified by preparative TLC (DCM / methanol=20:1, v / v) to obtain a yellow solid (170 mg, yield of 82%).

[0141] Step 2: Preparation of compound D1

[0142]

[0143] 2-Chloro-7H-pyrrolo[2,3-d]pyrimidine (9.4 g, 50 mmol) was dissolved in anhydrous t-BuOH (50 mL) and 2-chlorobenzyl bromide (10.6 mL, 60 mmol). After the addition was complete, the reaction was continued for 5 h. After TLC monitoring, the reaction solution was poured into ice water (500 mL) and extracted with EA (500 mL). The organic phase was washed with water twice, dried over anhydrous sodium sulfate, filtered and concentrated. Column chromatography (EA 15%, PE 85%, volume ratio) gave a white solid (14.3 g, yield 90%). 1 H NMR (400 MHz, CDCl 3 )δ8.66(s,1H),7.51(d,J=4.3Hz,1H),7.42(dd,J=7.9,0.8Hz,1H),7.23(dd,J=7.8,1.2Hz,1H),7.15(td,J=7.6,0.9Hz,1H ),7.03(s,2H),6.96(d,J=3.6Hz,1H),6.80(d,J=7.2Hz,1H),6.50(d,J=3.6Hz,1H),5.48(s,2H),3.80(s,3H),3.75(s,6H).

[0144] Example 20 Preparation of Compound D2

[0145]

[0146] Preparation analogy D1. 1H NMR (400 MHz, DMSO) δ 9.34 (s, 1H), 8.78 (s, 1H), 7.82 (d, J = 7.5 Hz, 1H), 7.53 (dt, J = 25.0, 7.4 Hz, 2H), 7.28 (d, J = 3.6 Hz, 1H), 7.19 (s, 2H), 6.63 (d, J = 7.7 Hz, 1H), 6.58 (d, J = 3.6 Hz, 1H), 5.62 (s, 2H), 3.56 (s, 3H), 3.55 (s, 6H).

[0147] Example 21 Preparation of Compound D3

[0148]

[0149] Preparation analogy D1. 1H NMR (400 MHz, DMSO) δ 9.34 (s, 1H), 8.72 (s, 1H), 7.38–7.28 (m, 3H), 7.22 (t, J = 7.7 Hz, 1H), 6.78 (dd, J = 28.6, 8.6 Hz, 3H), 6.48 (d, J = 3.0 Hz, 1H), 5.38 (s, 2H), 3.67 (s, 8H), 3.59 (s, 3H).

[0150] Example 22 Preparation of Compound D4

[0151]

[0152] Preparation analogy D1. 1H NMR (400 MHz, DMSO) δ 9.77 (s, 1H), 8.81 (s, 1H), 7.49 (d, J = 3.3 Hz, 1H), 7.38 (dd, J = 14.2, 7.9 Hz, 1H), 7.23–6.96 (m, 4H), 6.63 (d, J = 3.4 Hz, 2H), 5.44 (s, 2H), 3.67 (s, 6H), 3.62 (s, 3H).

[0153] Example 23 Preparation of Compound D5

[0154]

[0155] Preparation analogy D1. 1H NMR (400 MHz, DMSO) δ 9.39 (s, 1H), 8.75 (s, 1H), 7.71 (d, J = 8.1 Hz, 2H), 7.35 (t, J = 5.5 Hz, 3H), 7.28 (s, 2H), 6.53 (d, J = 3.5 Hz, 1H), 5.53 (s, 2H), 3.62 (s, 6H), 3.58 (s, 3H).

[0156] Example 24 Preparation of Compound D6

[0157]

[0158] Preparation analogy D1. 1 H NMR (400MHz, DMSO) δ9.37(s,1H),8.72(s,1H),7.40–7.29(m,3H),7.23(t,J=7.8Hz,1H),6.82(d,J=9.4Hz,2H ),6.75(d,J=7.5Hz,1H),6.48(d,J=3.5Hz,1H),5.38(s,2H),3.67(d,J=2.9Hz,6H),3.66(s,3H),3.59(s,3H).

[0159] Example 25 Preparation of Compound D7

[0160]

[0161] Preparation analogy D1. 1H NMR(400MHz,DMSO)δ9.38(s,1H),8.74(s,1H),7.44–7.20(m,5H),7.12(t,J=7.5Hz,1H ),6.88(t,J=7.6Hz,1H),6.53(d,J=3.5Hz,1H),5.48(s,2H),3.66(s,6H),3.59(s,3H).

[0162] Example 26 Preparation of Compound D8

[0163]

[0164] Preparation analogy D1. 1 H NMR (400MHz, DMSO) δ9.39 (s, 1H), 8.73 (s, 1H), 7.40 (d, J = 8.3Hz, 2H), 7.31 (d, J = 4.3Hz, 3 H),7.21(d,J=8.3Hz,2H),6.50(d,J=3.5Hz,1H),5.42(s,2H),3.66(s,6H),3.59(s,3H).

[0165] Example 27 Preparation of Compound D9

[0166]

[0167] Preparation analogy D1. 1 H NMR (400MHz, DMSO) δ9.38 (s, 1H), 8.73 (s, 1H), 7.53 (d, J = 8.3Hz, 2H), 7.31 (s, 3H), 7 .14(d,J=8.2Hz,2H),6.50(d,J=3.5Hz,1H),5.40(s,2H),3.66(s,6H),3.59(s,3H).

[0168] Example 28 Preparation of Compound D10

[0169]

[0170] Preparation analogy D1. 1 H NMR(400MHz,DMSO)δ9.38(s,1H),8.73(s,1H),7.36–7.23(m,5H),7.16(t,J =8.8Hz,2H),6.49(d,J=3.5Hz,1H),5.40(s,2H),3.67(s,6H),3.59(s,3H).

[0171] Example 29 Preparation of Compound D11

[0172]

[0173] Preparation analogy D1. 1 H NMR(400MHz,DMSO)δ9.39(s,1H),8.74(s,1H),7.43–7.22(m,6H),7.12(d,J =6.5Hz,1H),6.51(d,J=3.5Hz,1H),5.43(s,2H),3.66(s,6H),3.59(s,3H).

[0174] Example 30 Preparation of Compound D12

[0175]

[0176] Preparation analogy D1. 1 H NMR(400MHz,DMSO)δ9.39(s,1H),8.74(s,1H),7.55–7.39(m,2H),7.38–7.23(m, 4H),7.16(d,J=7.7Hz,1H),6.51(s,1H),5.43(s,2H),3.66(s,6H),3.59(s,3H).

[0177] Example 31 Preparation of Compound D13

[0178]

[0179] Preparation analogy D1. 1 H NMR (400MHz, DMSO) δ9.37 (s, 1H), 8.73 (s, 1H), 7.40–7.11 (m, 8H), 6.49 (d, J = 3.5Hz, 1H), 5.42 (s, 2H), 3.65 (s, 6H), 3.59 (s, 3H).

[0180] Example 32 Preparation of Compound D14

[0181]

[0182] Preparation analogy D1. 1 H NMR (400MHz, DMSO) δ9.35 (s, 1H), 8.73 (s, 1H), 7.63 (d, J = 6.0Hz, 2H), 7.36–7.26 (m, 3H), 7 .14(dt,J=15.7,7.7Hz,2H),6.50(d,J=3.5Hz,1H),5.39(s,2H),3.67(s,6H),3.60(s,3H).

[0183] Example 33 Preparation of Compound D15

[0184]

[0185] Preparation analogy D1. 1 H NMR (400MHz, DMSO) δ9.36 (s, 1H), 8.77 (s, 1H), 7.70 (d, J = 7.6Hz, 1H), 7.37–7.15 (m, 5 H),6.56(d,J=3.5Hz,1H),6.54–6.49(m,1H),5.44(s,2H),3.60(s,6H),3.57(s,3H).

[0186] Example 34 Preparation of Compound D16

[0187]

[0188] Preparation analogy D1. 1 H NMR (400MHz, DMSO) δ9.36 (s, 1H), 8.75 (s, 1H), 7.64 (d, J = 8.4Hz, 2H), 7.56 (t, J = 7.6Hz, 1H), 7.41 (d, J = 7.7Hz, 1 H),7.36(d,J=3.6Hz,1H),7.29(s,2H),6.52(d,J=3.5Hz,1H),5.55(d,J=19.2Hz,2H),3.64(s,6H),3.59(s,3H).

[0189] Example 35 Preparation of Compound D17

[0190]

[0191] Preparation analogy D1. 1 H NMR (400MHz, DMSO) δ9.37(s,1H),8.75(s,1H),8.14(dd,J=8.6,2.7Hz,1H),8.07(s,1H),7.64(d,J=5.7H z,2H),7.37(d,J=3.5Hz,1H),7.29(s,2H),6.54(d,J=3.5Hz,1H),5.57(s,2H),3.65(s,6H),3.59(s,3H).

[0192] Example 36 Preparation of Compound D18

[0193]

[0194] Preparation analogy D1. 1H NMR (400MHz, DMSO) δ9.35 (s, 1H), 8.74 (s, 1H), 7.93–7.78 (m, 2H), 7.47 (dd, J = 9.0, 3.9Hz, 2H), 7.34 (d, J=3.6Hz,1H),7.31(s,2H),6.51(d,J=3.6Hz,1H),5.50(s,2H),3.79(s,3H),3.65(s,6H),3.59(s,3H).

[0195] Example 37 Preparation of Compound D19

[0196]

[0197] Preparation analogy D1. 1 H NMR (400MHz, DMSO) δ9.37(s,1H),8.74(s,1H),7.76(d,J=7.1Hz,1H),7.68(s,1H),7.55(t,J=7.7Hz,1H),7. 48(d,J=7.9Hz,1H),7.34(d,J=3.6Hz,1H),7.29(s,2H),6.53(s,1H),5.48(s,2H),3.66(s,6H),3.60(s,3H).

[0198] Example 38 Preparation of Compound D20

[0199]

[0200] Preparation analogy D1. 1 H NMR (400MHz, DMSO) δ9.38 (s, 1H), 8.75 (s, 1H), 7.34 (d, J = 3.6Hz, 1H), 7.28 (s, 2H), 7.16 (ddd, J = 9.3, 5.7,2.0Hz,1H),6.87(d,J=6.4Hz,2H),6.53(d,J=3.6Hz,1H),5.45(s,2H),3.67(s,6H),3.60(s,3H).

[0201] Example 39 Preparation of Compound D21

[0202]

[0203] Preparation analogy D1. 1H NMR (400MHz, DMSO) δ9.38(s,1H),8.75(s,1H),7.85(d,J=8.7Hz,2H),7.61(t,J=7.7Hz,1H),7.45(d,J=7.8 Hz,1H),7.35(d,J=3.6Hz,1H),7.29(s,2H),6.53(d,J=3.6Hz,1H),5.54(s,2H),3.64(s,6H),3.59(s,3H).

[0204] Example 40 Preparation of Compound D22

[0205]

[0206] Preparation analogy D1. 1 H NMR (400MHz, DMSO) δ9.38(s,1H),8.75(s,1H),7.85(d,J=8.7Hz,2H),7.61(t,J=7.7Hz,1H),7.45(d,J=7.8Hz,1H ),7.35(d,J=3.6Hz,1H),7.29(s,2H),6.53(d,J=3.6Hz,1H),5.54(s,2H),3.64(s,6H),3.59(s,3H),3.18(s,3H).

[0207] Example 41 Preparation of Compound D23

[0208]

[0209] Preparation analogy D1. 1 H NMR (400MHz, DMSO) δ9.37 (s, 1H), 8.75 (s, 1H), 7.35 (t, J = 5.8Hz, 2H), 7.28 (s, 2H), 7.10 (s ,1H),7.00(d,J=9.2Hz,1H),6.53(d,J=3.6Hz,1H),5.44(s,2H),3.67(s,6H),3.60(s,3H).

[0210] Example 42 Preparation of Compound D24

[0211]

[0212] Preparation analogy D1. 1H NMR (400MHz, DMSO) δ9.37(s,1H),8.75(s,1H),7.62(d,J=8.4Hz,1H),7.47(s,1H),7.37(d ,J=3.5Hz,1H),7.27(s,3H),6.54(d,J=3.5Hz,1H),5.53(s,2H),3.65(s,6H),3.59(s,3H).

[0213] Example 43 Preparation of hydrochloride (taking the compound of Example 12 as an example)

[0214] Take an appropriate amount of the compound, dissolve it in ethanol, slowly introduce HCl gas at room temperature until saturation, cool it in an ice bath, and slowly precipitate white crystals, which are the hydrochloride of the compound.

[0215] Application Example 1:

[0216] 1. Experimental methods

[0217] FAK kinase activity was tested using the Lantha screen method with ATP concentration as Km. Prepare FAK solution in 1× kinase buffer at a concentration of 2 times the final concentration of each reagent. Add 5 μL of 1× kinase buffer to each well except for the control wells without enzyme. Prepare substrate solutions of fluorescein-PLLA and ATP in 1× kinase reaction buffer at a concentration of 2 times the final concentration of each reagent in the experiment. Add 5 μL of substrate solution to each well to start the reaction. Cover the experimental plate and incubate at room temperature for 30 minutes. Prepare detection solution in antibody dilution buffer at 2 times the final concentration. Add 10 μL of detection solution to each well to stop the reaction. Mix briefly with a centrifuge and incubate for 60 minutes before reading fluorescence on a microplate reader. Collect data on Envision at 340 nm excitation and 520 nm and 495 nm emission. Set up a positive control, which is the commercially available FAK inhibitor Defactinib.

[0218] 2. Experimental results

[0219] Table 1 below shows the inhibition of FAK kinase by the series of compounds synthesized by the present invention. 50 <50nM, "+++" means 50nM≤FAK IC 50 <100nM, “++” means 100nM≤FAK IC 50 <500nM, “+” represents FAKIC 50 >500nM.

[0220] Table 1 IC50 of compounds against FAK

[0221] B1 ++++ D4 +++ B2 ++++ D5 +++ B3 ++++ D6 +++ B4 ++++ D7 +++ B5 ++ D8 + B6 ++++ D9 + B7 ++++ D10 + B8 ++++ D11 + B9 ++ D12 +++ B10 ++++ D13 ++ B11 ++++ D14 +++ B12 ++++ D15 ++ B13 ++ D16 +++ B14 ++++ D17 ++ B15 ++++ D18 ++ B16 ++++ D19 +++ B17 ++++ D20 ++ B18 ++++ D21 ++ D1 ++ D22 ++ D2 ++ D23 +++ D3 ++ D24 ++

[0222] The above experimental results indicate that the compounds of the present invention have a certain inhibitory effect on FAK kinase.

[0223] In summary, the compounds of the present invention have a significant inhibitory effect on FAK kinase and can be used to prepare FAK inhibitors; they can also be used to prepare drugs for preventing and / or treating diseases related to FAK activity, such as preparing drugs for preventing and / or treating cancer, fibrotic diseases, autoimmune diseases, infectious diseases or cell proliferation disorders. At the same time, the compounds of the present invention have good pharmacokinetics and have broad application prospects.

Claims

1. A compound, characterized in that The compound is the following compound:

2. A pharmaceutically acceptable salt of the compound according to claim 1, characterized in that The pharmaceutically acceptable salt is a salt formed by the compound and hydrochloric acid.

3. Use of the compound according to claim 1 in the preparation of a drug for regulating the catalytic activity of protein kinase, wherein: The protein kinase is selected from the group consisting of focal adhesion kinases.

Citation Information

Patent Citations

  • Pyrazolylaminopyridines as inhibitors of fak

    US20100113475A1

  • Compounds for the treatment of abnormal cell growth

    WO2004056786A2

  • Pyrimidine derivatives for the treatment of abnormal cell growth

    WO2004056807A1

  • 2, 4- di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders

    WO2004080980A1

  • 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders

    WO2005016894A1